Modality
Multispecific
MOA
WEE1i
Target
HER2
Pathway
Lipid Met
NMOSD
Development Pipeline
Preclinical
May 2019
→ Mar 2029
PreclinicalCurrent
NCT08145395
259 pts·NMOSD
2022-09→2027-12·Not yet recruiting
NCT05905230
1,706 pts·NMOSD
2019-05→2029-03·Not yet recruiting
1,965 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-191.7y awayInterim· NMOSD
2029-03-072.9y awayInterim· NMOSD
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Not yet…
Preclinical
Not yet…
Catalysts
Interim
2027-12-19 · 1.7y away
NMOSD
Interim
2029-03-07 · 2.9y away
NMOSD
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08145395 | Preclinical | NMOSD | Not yet recr... | 259 | EDSS |
| NCT05905230 | Preclinical | NMOSD | Not yet recr... | 1706 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| Cevicapivasertib | Corcept | Phase 2 | CFTR |